Canaccord downgraded Intercept Pharmaceuticals to Hold from Buy with a price target of $19, down from $20, after Alfasigma agreed to acquire Intercept for $19 per share in cash.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ICPT:
- Intercept downgraded to Neutral from Buy at B. Riley
- Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
- Alfasigma to acquire Intercept for $19.00 per share in cash
- Intercept price target raised to $20 from $18 at Canaccord
- Intercept raises FY23 Ocaliva net sales view to $320M-$340M from $310M-$340M